Jetema announced on the 6th that it participated in the 'IMCAS World Congress 2026', the world's largest aesthetic medicine conference held in Paris, France in January, and shared its commercialization roadmap targeting the global market and next-generation research and development (R&D) strategy.
For the second consecutive year, Jetema was invited to participate in the "La Tribune" session, a key program where CEOs and economic analysts from global aesthetic medicine companies discuss industry trends. This year, Kim Byeong-su, Head of the Global Business Division, presented Jetema's technological competitiveness and market strategy.
This session noted that while the global medical aesthetics market is entering a period of overall slowdown, the filler market is maintaining relative growth. Jetema predicted that a total solution strategy based on a complex portfolio combining botulinum toxin, hyaluronic acid (HA) filler "Eptq," lifting threads, and skin boosters will be key to expanding its market share in the future.
In his presentation, CEO Kim Byung-soo explained the global competitiveness of Jetema's botulinum toxin product, "Zetemadertoxin," from two perspectives. Jetema successfully completed Phase 2 clinical trials in the US using its own capabilities, without external support, securing global-level R&D competitiveness. Building on this, the company unveiled a step-by-step roadmap aimed at entering the US market and commercializing the product by 2029. He also presented a plan to develop a treatment method in response to prejuvenation, a preventive treatment trend gaining popularity among younger generations.
Additionally, the research status of botulinum toxin type E, currently under development as a next-generation pipeline, was shared. Type E is characterized by rapid onset of action and a shorter duration of action compared to the existing type A, and was evaluated as a pipeline that demonstrates Jetema's technological strengths as a differentiated formulation that aligns with the latest treatment trends.
Kim Byung-soo, CEO of the company, stated that the company plans to pursue commercialization plans centered on the North American and European markets in the future based on global clinical performance and portfolio strategy.
- See more related articles
You must be logged in to post a comment.